Jubilant Life receives US FDA approval for hypertension drug telmisartan

The Noida-based pharmaceuticals major Jubilant Life Sciences Ltd has received the US Food and Drug Administration’s (FDA) approval for its hypertension drug telmisartan tablet in strengthens of 20 mg, 40 mg and 80 mg.

“The company has received Abbreviated New Drug Application (ANDA) final approval for telmisartan tablets, USP 20, 40 and 80 mg, the generic version of Micardis tablets of Boehringer Ingelheim Pharmaceuticals Inc, which is used for the treatment of hypertension,” said Jubilant Life Sciences in a press release.

As on June 30, 2016, the company had a total of 770 filings for oral solids of which 578 have been approved in various regions globally. This includes 70 ANDAs filed in the US, of which 44 have been approved and 104 filings in Europe.